Caribou Biosciences, Inc. (Nasdaq: CRBU), a prominent clinical-stage biopharmaceutical company specializing in CRISPR genome editing, has announced a webcast scheduled for 8:00 AM ET on Monday, November 3, 2025. The event will present new findings from the ANTLER phase 1 clinical trial involving vispacabtagene regedleucel (vispa-cel; previously known as CB-010), an allogeneic anti-CD19 CAR-T cell therapy aimed at patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Additionally, the webcast will shed light on the first clinical data from the CaMMouflage Phase 1 clinical trial concerning CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting patients with relapsed or refractory multiple myeloma (r/r MM).
During the webcast, the company will also outline the proposed design for the pivotal phase 3 trial of vispa-cel and discuss the next steps in the clinical development of CB-011. The live presentation can be accessed through Caribou”s website under the Events section, and an archived version will be available for 30 days following the event.
Vispacabtagene regedleucel is currently being evaluated for its effectiveness in treating patients with r/r B-NHL. According to Caribou, vispa-cel is distinguished as the first allogeneic CAR-T cell therapy in clinical trials to incorporate a PD-1 knockout, a genome-editing approach intended to enhance CAR-T cell functionality by reducing early exhaustion of these cells. The therapy has received several designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track for B-NHL. More details regarding the ANTLER trial can be found at clinicaltrials.gov (NCT04637763).
CB-011, on the other hand, is being studied in the CaMMouflage Phase 1 trial for patients with r/r MM. Caribou claims that CB-011 is the first allogeneic CAR-T cell therapy designed to function through an immune cloaking strategy, which involves a B2M knockout and the insertion of a B2M-HLA-E fusion protein to mitigate immune rejection. This therapy has also received Fast Track and Orphan Drug designations from the FDA. Additional information on the CaMMouflage trial is accessible at clinicaltrials.gov (NCT05722418).
Founded to create transformative therapies for severe diseases, Caribou Biosciences, Inc. leverages its advanced genome-editing platform, featuring the Cas12a chRDNA technology, to develop cell therapies aimed at enhancing treatment efficacy against various conditions. The company is concentrating on vispacabtagene regedleucel and CB-011 as ready-to-use CAR-T cell therapies that could facilitate wider access and prompt intervention for patients battling hematologic malignancies. For updates, follow the company on Twitter @CaribouBio and visit www.cariboubio.com.
For further inquiries, contact: Peggy Vorwald, PhD at [email protected] or [email protected].
